The Role of Ubiquitin and Ubiquitin-Like Molecules in Direct Antigen Presentation

泛素和泛素样分子在直接抗原呈递中的作用

基本信息

  • 批准号:
    10092081
  • 负责人:
  • 金额:
    $ 35.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-20 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Project Summary DESCRIPTION. The immune system must eliminate cells of the body that have become diseased as the result of intracellular infection or oncogenic transformation. CD8+ cytotoxic T cells are responsible for completing this task and must be able to distinguish healthy cells from diseased ones. Major Histocompatibility Complex Class I (MHC class I) molecules are present on most nucleated cells and are responsible for presenting antigen at the cell surface for CD8+ T cell inspection. In order to present antigen, the MHC class I pathway relies on binding to short peptides, created from degraded cellular proteins. When the source protein is associated with a disease (such as a viral protein or tumor associated protein) specific CD8+ T cells will recognize the peptide- MHC class I complex and kill the cell. Because the peptide provides the ultimate specificity in this reaction, we are interested in understanding how these peptides are created. Our data indicates that proteins which are rapidly degraded following their synthesis (termed Defective Ribosomal Proteins or DRiPs) are responsible for efficiently generating a supply of peptides. This proposal seeks to determine which cellular metabolic pathways are used to direct the rapid degradation of DRiPs and to determine if DRiPs are necessary in physiologically relevant settings. We are focusing on the ubiquitin conjugation pathway, as ubiquitin coupling is intimately associated with protein degradation. Ubiquitin-like proteins (UBLs) may also play a role in direct antigen presentation. The Specific Aims of this proposal are to identify how the ubiquitin-modifying enzyme Usp14 interacts with the antigen presentation machinery, understand why conjugation of the ubiquitin-like molecule Nedd8 is necessary for DRiP antigen presentation, and determine which E3 ubiquitin ligases are necessary for DRiP antigen presentation.
项目摘要 说明.免疫系统必须消除身体的细胞,这些细胞因此而患病 细胞内感染或致癌转化。CD8+细胞毒性T细胞负责完成这一过程。 必须能够区分健康细胞和病变细胞。类主要组织相容性复合 I(MHC I类)分子存在于大多数有核细胞上,并负责在细胞内呈递抗原。 细胞表面进行CD8+ T细胞检查。为了呈递抗原,MHC I类途径依赖于 与降解的细胞蛋白质产生的短肽结合。当源蛋白与 疾病(如病毒蛋白或肿瘤相关蛋白)特异性CD8+ T细胞将识别所述肽。 MHC I类复合体并杀死细胞。由于肽在该反应中提供了最终的特异性,我们 有兴趣了解这些肽是如何产生的。我们的数据表明, 在它们合成后迅速降解的蛋白质(称为缺陷核糖体蛋白质或DRiP)负责 有效地产生肽的供应。这项建议旨在确定哪些细胞代谢 途径用于指导DRiPs的快速降解,并确定DRiPs是否是必需的。 生理相关的设置。我们关注的是泛素结合途径,如泛素偶联 与蛋白质降解密切相关。泛素样蛋白(UBLs)也可能在直接免疫中发挥作用。 抗原呈递这项提议的具体目的是确定泛素修饰酶如何 Usp14与抗原呈递机制相互作用,理解为什么泛素样结合 分子Nedd8是DRiP抗原呈递所必需的,并确定哪些E3泛素连接酶是 DRiP抗原呈递所必需的。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.
  • DOI:
    10.1128/jvi.00256-22
  • 发表时间:
    2022-09-14
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Kazemi, Soheila;Lopez-Munoz, Alberto Domingo;Holly, Jaroslav;Jin, Ling;Yewdell, Jonathan W.;Dolan, Brian P.
  • 通讯作者:
    Dolan, Brian P.
Direct Conjugation of NEDD8 to the N-Terminus of a Model Protein Can Induce Degradation.
NEDD8与模型蛋白的N末端的直接结合可以诱导降解。
  • DOI:
    10.3390/cells10040854
  • 发表时间:
    2021-04-09
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Vijayasimha K;Tran MV;Leestemaker-Palmer AL;Dolan BP
  • 通讯作者:
    Dolan BP
MLN4924 Inhibits Defective Ribosomal Product Antigen Presentation Independently of Direct NEDDylation of Protein Antigens.
  • DOI:
    10.4049/jimmunol.2100584
  • 发表时间:
    2022-05-15
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Vijayasimha, Kartikeya;Leestemaker-Palmer, Amy L.;Gibbs, James S.;Yewdell, Jonathan W.;Dolan, Brian P.
  • 通讯作者:
    Dolan, Brian P.
Quantitating MHC Class I Ligand Production and Presentation Using TCR-Like Antibodies.
使用 TCR 样抗体定量 MHC I 类配体的产生和呈现。
The Many Potential Fates of Non-Canonical Protein Substrates Subject to NEDDylation.
  • DOI:
    10.3390/cells10102660
  • 发表时间:
    2021-10-05
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Vijayasimha K;Dolan BP
  • 通讯作者:
    Dolan BP
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian Paul Dolan其他文献

Brian Paul Dolan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian Paul Dolan', 18)}}的其他基金

Chlamydia-induced host protein degradation and its impact on the adaptive immune response.
衣原体诱导的宿主蛋白降解及其对适应性免疫反应的影响。
  • 批准号:
    9232073
  • 财政年份:
    2016
  • 资助金额:
    $ 35.22万
  • 项目类别:
Chlamydia-induced host protein degradation and its impact on the adaptive immune response.
衣原体诱导的宿主蛋白降解及其对适应性免疫反应的影响。
  • 批准号:
    9015725
  • 财政年份:
    2016
  • 资助金额:
    $ 35.22万
  • 项目类别:
Ubiquitin conjugation and direct MHC class I antigen presentation
泛素结合和直接 MHC I 类抗原呈递
  • 批准号:
    8880646
  • 财政年份:
    2014
  • 资助金额:
    $ 35.22万
  • 项目类别:
Identification and characterization of cellular mechanisms which selectively cont
选择性控制细胞机制的鉴定和表征
  • 批准号:
    8188767
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:
Identification and characterization of cellular mechanisms which selectively cont
选择性控制细胞机制的鉴定和表征
  • 批准号:
    8487345
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:

相似海外基金

RNA vaccine that exerts antitumor effect via non-canonical antigen presentation pathway
通过非经典抗原呈递途径发挥抗肿瘤作用的RNA疫苗
  • 批准号:
    19K07782
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Climate change and fish disease: In vivo and in vitro studies of the modulation of the teleost antigen presentation pathway in response to thermal stress and viral infection using two different system
气候变化和鱼类疾病:使用两种不同的系统对硬骨鱼抗原呈递途径的调节响应热应激和病毒感染进行体内和体外研究
  • 批准号:
    469000-2014
  • 财政年份:
    2015
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Banting Postdoctoral Fellowships Tri-council
Climate change and fish disease: In vivo and in vitro studies of the modulation of the teleost antigen presentation pathway in response to thermal stress and viral infection using two different system
气候变化和鱼类疾病:使用两种不同的系统对硬骨鱼抗原呈递途径的调节响应热应激和病毒感染进行体内和体外研究
  • 批准号:
    469000-2014
  • 财政年份:
    2014
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Banting Postdoctoral Fellowships Tri-council
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8652945
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8466919
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    9054767
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8373738
  • 财政年份:
    2012
  • 资助金额:
    $ 35.22万
  • 项目类别:
Investigation of the HLA class II Antigen Presentation Pathway in Estrogen Receptor Negative and Estrogen Receptor Positive Breast Carcinoma.
雌激素受体阴性和雌激素受体阳性乳腺癌中 HLA II 类抗原呈递途径的研究。
  • 批准号:
    186899
  • 财政年份:
    2009
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Fellowship Programs
Down regulation of antigen presentation pathway plays an important role in metastasis and progression of advanced stage of epithelial ovarian cancer.
抗原呈递途径的下调在上皮性卵巢癌晚期的转移和进展中发挥重要作用。
  • 批准号:
    21390449
  • 财政年份:
    2009
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
New anti-tuberculosis vaccine strategies by the use of the CD1-lipid antigen presentation pathway
利用 CD1-脂质抗原呈递途径的新抗结核疫苗策略
  • 批准号:
    15390317
  • 财政年份:
    2003
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了